Neurocrine Biosciences Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788.1M | $451.2M |
| Cost of Revenue | $52.1M | $34.0M | $39.7M | $23.2M | $14.3M | $10.1M | — | $4.9M |
| Gross Profit | $2.81B | $2.32B | $1.85B | $1.47B | $1.12B | $1.04B | — | $446.3M |
| Gross Margin | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | — | 98.9% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | $160.5M |
| SG&A Expense | $1.16B | $1.01B | $887.6M | $752.7M | $583.3M | $433.3M | $354.1M | $248.9M |
| Operating Income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M | $163.0M | $72.3M | $36.8M |
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% |
| Interest Expense | — | — | $4.6M | $7.1M | $25.8M | $32.8M | $32.0M | $30.5M |
| Pretax Income | $705.4M | $486.0M | $332.1M | $213.9M | $101.4M | $106.7M | $46.5M | $21.8M |
| Income Tax Expense | $226.8M | $144.7M | $82.4M | $59.4M | $11.8M | $-300.6M | $9.5M | $700.0K |
| Net Income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M | $37.0M | $21.1M |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% |
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 |
| Shares Outstanding (Basic) | 99.5M | 100.4M | 97.7M | 95.8M | 94.6M | 93.1M | 91.6M | 90.2M |
| Shares Outstanding (Diluted) | 102.5M | 103.7M | 101.0M | 98.9M | 97.9M | 97.8M | 95.7M | 95.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |